Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal Balloons

Author:

Forsthoefel Matthew1,Hankins Ryan2,Ballew Elizabeth1,Frame Cara1,DeBlois David1,Pang Dalong1,Krishnan Pranay3,Unger Keith1,Kowalczyk Keith2,Lynch John2,Dritschilo Anatoly1,Collins Sean P.1,Lischalk Jonathan W.4

Affiliation:

1. 1 Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA.

2. 2 Department of Urology, Georgetown University Hospital, Washington, DC, USA.

3. 3 Department of Radiology, Georgetown University Hospital, Washington, DC, USA.

4. 4 Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital – Long Island, New York, NY, USA

Abstract

Abstract Purpose Proton beam radiotherapy (PBT) has been used for the definitive treatment of localized prostate cancer with low rates of high-grade toxicity and excellent patient-reported quality-of-life metrics. Technological advances such as pencil beam scanning (PBS), Monte Carlo dose calculations, and polyethylene glycol gel rectal spacers have optimized prostate proton therapy. Here, we report the early clinical outcomes of patients treated for localized prostate cancer using modern PBS–PBT with hydrogel rectal spacing and fiducial tracking without the use of endorectal balloons. Materials and Methods This is a single institutional review of consecutive patients treated with histologically confirmed localized prostate cancer. Prior to treatment, all patients underwent placement of fiducials into the prostate and insertion of a hydrogel rectal spacer. Patients were typically given a prescription dose of 7920 cGy at 180 cGy per fraction using a Monte Carlo dose calculation algorithm. Acute and late toxicity were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE), version 5. Biochemical failure was defined using the Phoenix definition. Results From July 2018 to April 2020, 33 patients were treated (median age, 75 years). No severe acute toxicities were observed. The most common acute toxicity was urinary frequency. With a median follow-up of 18 months, there were no high-grade genitourinary late toxicities; however, one grade 3 gastrointestinal toxicity was observed. Late erectile dysfunction was common. One treatment failure was observed at 21 months in a patient treated for high-risk prostate cancer. Conclusion Early clinical outcomes of patients treated with PBS–PBT using Monte Carlo–based planning, fiducial placement, and rectal spacers sans endorectal balloons demonstrate minimal treatment-related toxicity with good oncologic outcomes. Rectal spacer stabilization without the use of endorectal balloons is feasible for the use of PBS–PBT.

Publisher

International Journal of Particle Therapy

Subject

Radiology, Nuclear Medicine and imaging,Atomic and Molecular Physics, and Optics

Reference42 articles.

1. Shipley WU, Tepper JE, Prout GR, Verhey LJ, Mendiondo OA, Goitein M, Koehler AM, Suit HD. Proton radiation as boost therapy for localized prostatic carcinoma. JAMA. 1979; 241:1912–5.

2. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American college of radiology 95-09. J Clin Oncol. 2010; 28: 1106– 11.

3. Bryant C, Smith TL, Henderson RH, Hoppe BS, Mendenhall WM, Nichols RC, Morris CG, Williams CR, Su Z, Li Z, Lee D, Mendenhall NP. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2016; 95: 422– 34.

4. Efstathiou J. Prostate advanced radiation technologies investigating quality of life (PARTIQoL): a phase III randomized clinical trial of proton therapy vs IMRT for low or intermediate risk prostate cancer. ClinicalTrials.gov.identifier : NCT01617161. Accessed October 2021. https://clinicaltrials.gov/ct2/show/NCT01617161

5. Kirk ML, Tang S, Zhai H, Vapiwala N, Deville C, James P, Bekelman JE, Christodouleas JP, Tochner Z, Both S. Comparison of prostate proton treatment planning technique, interfraction robustness, and analysis of single-field treatment feasibility. Pract Radiat Oncol. 2015; 5: 99– 105.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3